CHD7 associated with survival in pancreatic ductal adenocarcinoma patients receiving gemcitabine
As reported in Cancer Research, low CHD7 expression is associated with increased RFS and OS in pancreatic ductal adenocarcinoma patients receiving gemcitabine. There was no association between CHD7 expression and RFS or OS in patients who were not treated with gemcitabine.
VPAC1 overexpression associated with colon cancer aggression
As reported in Tumor Biology, VPAC1 expression is increased in poorly differentiated compared to well-differentiated colon cancer. VPAC1 expression is also increased in the blood vessels and macrophages adjacent to colon cancer tissues compared to healthy tissues. The overexpression of VPAC1 is related to EGFR overexpression.
CTC count predicts survival in mBC
As reported in The Lancet Oncology, circulating tumor cell (CTC) quantification in patients (20 studies; n = 1944) with metastatic breast cancer (mBC) predicts progression-free survival (PFS) and overall survival (OS), especially when coupled with clinicopathologic data. A CTC count ≥ 5/7.5 mL at baseline is associated with decreased PFS (HR = 1.92) and OS (HR = 2.78). An elevated CTC count 3-5 weeks and 6-8 weeks after treatment commences is also associated with decreased PFS (HR = 1.85 and 2.20) and OS (HR = 2.26 and 2.91).